Chicago Capital LLC Has $10.01 Million Stock Holdings in Johnson & Johnson $JNJ

Chicago Capital LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 65,512 shares of the company’s stock after acquiring an additional 3,865 shares during the period. Chicago Capital LLC’s holdings in Johnson & Johnson were worth $10,007,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Trivium Point Advisory LLC grew its stake in Johnson & Johnson by 11.2% during the second quarter. Trivium Point Advisory LLC now owns 11,231 shares of the company’s stock worth $1,716,000 after purchasing an additional 1,131 shares during the period. G&S Capital LLC grew its stake in Johnson & Johnson by 1.4% during the second quarter. G&S Capital LLC now owns 4,995 shares of the company’s stock worth $763,000 after purchasing an additional 69 shares during the period. Capital Investment Advisors LLC grew its stake in Johnson & Johnson by 2.2% during the second quarter. Capital Investment Advisors LLC now owns 434,565 shares of the company’s stock worth $66,380,000 after purchasing an additional 9,532 shares during the period. Bennett Selby Investments LP grew its stake in Johnson & Johnson by 3.2% during the second quarter. Bennett Selby Investments LP now owns 18,125 shares of the company’s stock worth $2,769,000 after purchasing an additional 567 shares during the period. Finally, Presper Financial Architects LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $278,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Morgan Stanley raised their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.40.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.3%

Shares of NYSE:JNJ opened at $185.99 on Thursday. The stock has a market cap of $447.92 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $186.56. The business’s 50 day moving average is $175.45 and its 200 day moving average is $162.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.